Clinical trials: COVID-19 Convalescent Plasma Treatment
Infectious Disease
Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series
This is the first Case Studies article highlight factors determine the effectiveness of Convalescent Plasma Therapy (CPT) in Indonesia, accompanied by supporting data and images before and after the patients received the therapy.
- Trial name
- NCT05046652
- Testing
- Convalescent Plasma Therapy
- Where
- Indonesia
- Volunteers
- 8 people
- Sponsor
- Maranatha Christian University
Corona Virus Infection
Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions
This study will provide access to investigational anti-SARS-CoV-2 human convalescent plasma for pediatric patients with underlying medical conditions (cardiovascular disease, lung disease, immunosuppression) who are either…
- Trial name
- NCT04462848
- Testing
- anti-SARS-CoV-2 human convalescent plasma
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Covid19, Convalescence
Convalescent Plasma Therapy in Severe COVID-19 Infection
As of March 18, 2020, COVID-19 cases were reported in approximately 195 countries. No specific therapeutic agents or vaccines for COVID-19 are available.
- Trial name
- NCT04403477
- Testing
- Convalescent plasma
- Where
- Bangladesh
- Volunteers
- 20 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
COVID-19
Convalescent Plasma Therapy - Zurich Protocol
This is an open-label, single-center, phase I study to assess the safety and efficacy of convalescent plasma therapy (CPT) obtained from donors who were tested positive for SARS-CoV-2 and fully recovered from the infection and…
- Trial name
- CPT-ZHP (NCT04869072)
- Testing
- Convalescent plasma
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Zurich
COVID, Sars-CoV2
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19
The purpose of this program is to see if giving convalescent plasma to individuals who test positive for COVID-19 may reduce their symptoms and help minimize complications from the illness.
- Conditions
- COVID, Sars-CoV2, Corona Virus Infection
- Trial name
- NCT04445207
- Testing
- Convalescent Plasma
- Where
- United States
- Sponsor
- Jonathan Gerber
COVID19, Coronavirus Infection
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
This is a prospective study, using plasma to help fight off infections of those suffering from COVID-19 in accordance with collection guidelines for plasma and FDA IND requirements.
- Conditions
- COVID19, Coronavirus Infection, Coronavirus, Virus Diseases
- Trial name
- NCT04376034
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- West Virginia University
COVID
Convalescent Plasma in Pediatric COVID-19
COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been adequately studied in children to date. The study will determine safety of convalescent plasma for pediatric patients with severe, or at high…
- Trial name
- NCT04458363
- Testing
- Convalescent Plasma (CP), Standard COVID-19 therapies
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
COVID-19, SARS-CoV 2
CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19
The present study will try to respond first in an initial phase, what is the minimum effective dose necessary of convalescent plasma for getting better in severly ill (not intubated) or very severely ill (intubated) patients.
- Conditions
- COVID-19, SARS-CoV 2, Convalescence, Plasma
- Trial name
- COPLASCOV19 (NCT04356482)
- Testing
- convalescent plasma
- Where
- 3 sites in Mexico
- Volunteers
- 90 people
- Sponsor
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia, Pneumonia, Viral
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
Due to the limitations of COVID-19 treatment and in the absence of licensed antiviral for COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered especially against RNA viruses .It was known that…
- Trial name
- NCT04474340
- Testing
- COVID-19 Convalscent Plasma
- Where
- Kuwait
- Volunteers
- 300 people
- Sponsor
- Ministry of Health, Kuwait
COVID-19 Pneumonia
Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia
Background: On December 2019, a new human coronavirus infection (COVID-19) was detected in China. Its infectivity and virulence characteristics caused a rapid spread, being declared pandemic on March 2020.
- Trial name
- NCT04381858
- Testing
- Plasma from COVID-19 convalescent patient, Human immunoglobulin
- Where
- Mexico
- Volunteers
- 196 people
- Sponsor
- Centenario Hospital Miguel Hidalgo
COVID-19 Infection, Cancer Patients
COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)
COVID-19 infection has spread worldwide causing several deaths in few months Convalescent Plasma from COVID 19 donors has shown huge activity in small series from Chinese patients and currently many centers from USA and the…
- Conditions
- COVID-19 Infection, Cancer Patients, General Population
- Trial name
- FALP-COVID (NCT04384588)
- Testing
- Convalescent Plasma from COVID-19 donors
- Where
- Chile
- Volunteers
- 100 people
- Sponsor
- Fundacion Arturo Lopez Perez
COVID-19
Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19
Research Question: Does convalescent plasma (CCP) collected from donors who have recovered from COVID-19 and who have a very high titre of anti-SARS-CoV-2 antibodies reduce the risk of hospitalisation (for COVID-19) or death in…
- Trial name
- COVIC-19 (NCT05271929)
- Testing
- Current standard of care and COVID-19 convalescent and vaccinated plasma, Current standard of care
- Where
- 14 sites in France, Germany and 2 more
- Volunteers
- 120 people
- Sponsor
- Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen
SARS-CoV Infection
Convalescent Plasma Therapy for COVID-19 Patients
Passive immunization involves the administration of antibodies against a given agent to a susceptible individual for the purpose of preventing or treating an infectious disease due to that agent.
- Trial name
- NCT04565197
- Testing
- convalescent plasma
- Where
- Pakistan
- Volunteers
- 20 people
- Sponsor
- Lahore General Hospital
Severe Acute Respiratory Syndrome Coronavirus 2
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
This treatment protocol is designed to provide convalescent plasma as a therapeutic option for patients diagnosed with and hospitalized for COVID-19 with symptoms ranging from mild to life-threatening.
- Trial name
- NCT04360486
- Testing
- Anti-Sars-CoV-2 Convalescent Plasma
- Where
- 38 sites in United States, Afghanistan and 6 more
- Sponsor
- U.S. Army Medical Research and Development Command
Coronavirus
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the COVID-19 patients using…
- Trial name
- NCT04292340
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Public Health Clinical Center
Hospitalized Children, Covid-19 Infection
Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children
This is a multicentered, open-label, randomized controlled Phase 2 trial to evaluate the safety and efficacy of providing human coronavirus-immune convalescent plasma as treatment for COVID-19 disease in hospitalized children in…
- Trial name
- CONCOR-KIDS (NCT04377568)
- Testing
- Convalescent plasma (CP)
- Where
- 13 sites in Canada
- Sponsor
- The Hospital for Sick Children
COVID, Infectious Disease
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy
In this study, investigators will determine whether the early addition of HT-CCP to standard treatment improves the clinical outcome (as assessed by the Modified WHO Ordinal Scale) of patients with COVID-19 who are hospitalized…
- Trial name
- (ESCAPE) (NCT04361253)
- Testing
- High-Titer COVID-19 Convalescent Plasma (HT-CCP), Standard Plasma (FFP)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Brigham and Women's Hospital
COVID-19
Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support
The COVID-19 pandemic has been spreading continuously, and in Brazil, until August 18, 2020, there have been more than 3,359,000 cases with more than 108,536 deaths, with daily increases.
- Trial name
- NCT04528368
- Testing
- Convalescent plasma
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- D'Or Institute for Research and Education